Hasan SUNAR, Orkut GÜÇLÜ, Hakan KARADAĞ, Suat CANBAZ, Serhat HÜSEYİN, Ganime MISIRLIOĞLU, Volkan YÜKSEL, Turan EGE

Prostaglandin E1, prostaglandin I2 ve papaverinin internal torasik arter grefti üzerine in vitro etkileri

Amaç: Bu çalışmada prostaglandin E1, prostaglandin I2 ve papaverinin koroner arter baypas greft ameliyatlarında kullanılan internal torasik arter greftleri üzerine etkileri araştırıldı.Çalışmaplanı:Mart 2013 - Eylül 2013 tarihleri arasında kliniğimizde ameliyat edilen 10 hasta (9 erkek, 1 kadın; ort. yaş 53.7 yıl; dağılım 46-68 yıl) çalışmaya alındı. Prostaglandin E1 ve prostaglandin I2'nin 10-9 M-10-2.5 M konsantrasyon aralığında internal torasik arterde doza bağımlı etkileri gözlendi.Bul gu lar: Prostaglandin I2'nin internal torasik arter greftindeki gevşeme yanıtı prostaglandin E1'den daha güçlü iken, en güçlü gevşeme yanıtı papaverinin idi.So nuç: Aterosklerotik kardiyovasküler hastalıklar ve periferik damar hastalıkları gibi birçok kardiyovasküler hastalığın tedavisinde kullanılan prostaglandin E1 ve prostaglandin I2 internal torasik arter greftlerinde vazokonstriksiyonu önleyebilir. Greft açıklığı artırılarak ameliyat sırası mortalite ve morbiditenin azaltılmasına ilişkin ileri klinik çalışmalar gereklidir.

In vitro effects of prostaglandin E1, prostaglandin I2 and papaverine on internal thoracic artery graft

Background: This study aims to investigate the effects of prostaglandin E1, prostaglandin I2, and papaverine on internal thoracic artery grafts which are used during coronary artery bypass graft operations.Methods: Ten patients (9 males, 1 female; mean age 53.7 years; range 46 to 68 years) who were operated in our clinic between March 2013 and September 2013 were enrolled in the study. Dose-dependent effects of prostaglandin E1 and prostaglandin I2 on internal thoracic artery at a concentration interval of 10-9 M-10-2.5 M were observed.Results: While prostaglandin I2 had stronger relaxation response than prostaglandin E1 on internal thoracic artery graft, papaverine had the strongest relaxation response.Conclusion: Prostaglandin E1 and prostaglandin I2, which are used in the treatment of many aterosclerotic cardiovascular and peripheral artery diseases, may prevent vasoconstriction in internal thoracic artery grafts. Further clinical studies are required regarding decreasing perioperative mortality and morbidity by increasing graft patency.

PDF

___

1. Green GE. Rate of blood flow from the internal mammary artery. Surgery 1971;70:809-13.
2. Barner HB. Arterial grafting: techniques and conduits. Ann Thorac Surg 1998;66:2-5.
3. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, et al. Influence of the internal-mammaryartery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6.
4. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-58.
5. Dignan RJ, Yeh T Jr, Dyke CM, Lee KF, Lutz HA, Ding M, et al. Reactivity of gastroepiploic and internal mammary arteries. Relevance to coronary artery bypass grafting. J Thorac Cardiovasc Surg 1992;103:116-22.
6. He GW, Acuff TE, Ryan WH, Yang CQ, Mack MJ. Functional comparison between the human inferior epigastric artery and internal mammary artery. Similarities and differences. J Thorac Cardiovasc Surg 1995;109:13-20.
7. Cho KR, Kim JS, Choi JS, Kim KB. Serial angiographic follow-up of grafts one year and five years after coronary artery bypass surgery. Eur J Cardiothorac Surg 2006;29:511-6.
8. Wei W, Floten HS, He GW. Interaction between vasodilators and vasopressin in internal mammary artery and clinical significance. Ann Thorac Surg 2002;73:516-22.
9. Singh RN. Atherosclerosis and the internal mammary arteries. Cardiovasc Intervent Radiol 1983;6:72-7.
10. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
11. Chaikhouni A, Crawford FA, Kochel PJ, Olanoff LS, Halushka PV. Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Surg 1986;92:88-91.
12. He GW, Rosenfeldt FL, Buxton BF, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation 1989;80:I141-50.
13. Lin PJ, Chang CH, Pearson PJ, Tzen KY, Chu JJ, Chang JP, et al. Thromboxane A2: an endothelium-derived vasoconstrictor in human internal mammary arteries. Ann Thorac Surg 1993;56:97-100.
14. Hata M, Shiono M, Orime Y, Yagi S, Yamamoto T, Okumura H, et al. Clinical results of coronary artery bypass grafting with use of the internal thoracic artery under low free flow conditions. J Thorac Cardiovasc Surg 2000;119:125-9.
15. He GW, Buxton BF, Rosenfeldt FL, Angus JA, Tatoulis J. Pharmacologic dilatation of the internal mammary artery during coronary bypass grafting. J Thorac Cardiovasc Surg 1994;107:1440-4.
16. Mussa S, Choudhary BP, Taggart DP. Radial artery conduits for coronary artery bypass grafting: current perspective. J Thorac Cardiovasc Surg 2005;129:250-3.
17. Chanda J, Canver CC. Reversal of preexisting vasospasm in coronary artery conduits. Ann Thorac Surg 2001;72:476-80.
18. Sivalingam S, Levine A, Dunning J. What is the optimal vasodilator for preventing spasm in the left internal mammary artery during coronary arterial bypass grafting? Interact Cardiovasc Thorac Surg 2005;4:365-71.
19. Sivalingam S, Levine A, Dunning J. What is the optimal vasodilator for preventing spasm in the left internal mammary artery during coronary arterial bypass grafting? Interact Cardiovasc Thorac Surg 2005;4:365-71.
20. Haider DG, Bucek RA, Giurgea AG, Maurer G, Glogar H, Minar E, et al. PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial ce lls. Am J Physiol Heart Circ Physiol 2005;289:2066-72.
21. Chatziioannou A, Dalakidis A, Katsenis K, Koutoulidis V, Mourikis D. Intra-arterial prostaglandin e(1) infusion in patients with rest pain: short-term results. ScientificWorldJournal 2012;2012:803678.
22. Ege T, Gur O, Karadag CH, Duran E. Evaluation of iloprost to prevent vasospasm in coronary artery bypass grafts. J Int Med Res 2010;38:1759-63.
23. Gur O, Ege T, Gurkan S, Ozkaramanli Gur D, Karadag H, Cakir H, et al. In vitro effects of lidocaine hydrochloride on coronary artery bypass grafts. J Cardiovasc Surg (Torino) 2012;53:665-9.